ARASENS
Feb 22, 2022
Nubeqa (darolutamide) increases overall survival in men with mCSPC/HSPC when added to androgen-deprivation treatment (ADT) with docetaxel: ARASENS phase III study
According to the findings of the ARASENS trial (NCT02799602), presented by Bayer at the 2022 ASCO GU, Nubeqa resulted in a 32.5% reduction in the risk of death, with a median follow-up of 43.7 months for darolutamide. Nubeqa provided a consistent overall survival advantage across predefined subgroups. The med...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
